Skip to main content
Premium Trial:

Request an Annual Quote

BioMérieux Q3 Revenues Up 13 Percent

NEW YORK – BioMérieux reported on Tuesday that its third quarter revenues grew 13 percent year over year.

For the three months ended Sept. 30, the Marcy l'Étoile, France-based in vitro diagnostics firm recorded revenues of €653.1 million ($727.2 million) compared to €579.3 million in the year-ago period. Organic growth, at constant exchange rates and scope of consolidation, was approximately 10 percent year over year.

Revenues for the clinical applications business, which includes microbiology, molecular biology, immunoassays rose 13 percent to €536.6 million from €473.2 million a year ago.

Within clinical applications, microbiology rose 7 percent to €259.0 million from €243.1 million in Q3 2018, mainly fueled by growth in reagent sales for Vitek and BACT/ALERT systems.

Molecular biology sales increased 26 percent to €151.3 million from €120 million in Q3 2018, with 25 percent growth in the BioFire FilmArray product line supported by ongoing and rapid growth in international sales. BioMérieux noted that the FilmArray installed base grew to 9,800 units, with a key event in the quarter being the clearance and the reimbursement of the Respiratory Panel in Japan.

Revenues from immunoassay clinical applications rose 14 percent on a reported basis to €117.6 million from €103.3 million a year ago. The firm attributed the growth to recovery of sales in the Middle East and solid growth in the Asia Pacific region. It further noted that the impact of the price decrease on procalcitonin assays in the US was less pronounced during the quarter compared to previous quarters.

Meanwhile, revenues for the industrial applications business grew 10 percent to €116.5 million from €106.1 million in Q3 2018.

BioMérieux said that sales within clinical applications accounted for approximately 82 percent of total revenues in Q3, representing a year-over-year increase of almost 10 percent.

In the quarter the firm said it also received clearance from the National Medical Products Administration in China for the BACT/ALERT VIRTUO automated blood culture system and resin-based blood culture bottles.

The firm noted that organic growth is expected to be approximately 7 percent for the full year.